Cambridge Antibody Technology (officially Cambridge Antibody Technology Group Plc, informally CAT) was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using phage display and ribosome display technology.Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug.